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Background: We tested the hypothesis that sodium-hydrogen exchange inhibition
attenuates ventricular dysfunction after ischemia-reperfusion injury in the intact
porcine heart.
Methods: Twelve pigs (weight, 30-45 kg) were evenly divided into 2 groups.
Baseline ventricular function studies were based on echocardiography, conductance,
aortic flow, and left ventricular pressure. Animals were given vehicle (control) or
benzamide-N-(aminoiminomethl)-4-(4-[2-furanylcarbonyl]-1-piperazinyl)-3-(meth-
ylsulfonyl)methanesulfonate (BIIB 513; 3 mg/kg administered intravenously). Ten
minutes later, hearts were subjected to 75 seconds of ventricular fibrillation. After
reperfusion for 40 minutes, function studies were repeated. Hearts were arrested and
excised. Postmortem data included passive pressure-volume curves and myocardial
water content.
Results: Preload recruitable stroke work was significantly decreased from baseline
after ischemia and reperfusion in the control group (27.7  2.5 vs 48.0  5.6 mm
Hg [ SEM], P  .001) but not in the BIIB 513 group (43.0  5.8 vs 45.5  4.1
mm Hg, P  not significant). In vivo diastolic and postmortem passive left
ventricular compliance were reduced after ischemia and reperfusion for control
animals but remained unchanged for animals receiving BIIB 513. Time required to
recover baseline blood pressure after ventricular fibrillation was significantly longer
for control animals (159 15 vs 88 14 seconds [ SEM], P .008). Myocardial
water content (78.97% 0.94% vs 77.86% 0.46% [ SEM]) and normalized left
ventricular mass (137.24  6.17 vs 128.41  1.96 g [ SEM]) were insignificantly
increased in control animals.
Conclusions: Sodium-hydrogen exchange inhibition attenuates ventricular dysfunction
after 75 seconds of ventricular fibrillation and 40 minutes of reperfusion. This family of
agents might prove useful in patients with severe left ventricular dysfunction undergoing
ventricular fibrillation for implantable cardioverter defibrillator testing.
Implantable cardioverter-defibrillators (ICDs) are effective treatment forrefractory malignant arrhythmias, decreasing the incidence of sudden ar-rhythmic death to 1% to 2% per year.1-3 Insertion requires induction ofventricular fibrillation (VF) to measure defibrillation thresholds (DFTs).ICD recipients often have markedly decreased ventricular function causedby cardiomyopathy, infarct-related scars, or left ventricular (LV) aneu-
rysms.1 Although perioperative mortality for routine ICD insertion is low (0.5%-
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5%), eligibility has been expanded to patients formerly
thought to be too ill (eg, patients with ventricular arrhyth-
mias awaiting heart transplantation or patients with ejection
fractions [EFs] of 10% or less).3,4 DFT testing in some of
these patients is considered too hazardous and is deferred. A
small study from our laboratory revealed no mean change in
intraoperative EF after ICD testing,5 but there was consid-
erable individual variation between patients. Also, cardio-
vascular collapse has been reported during ICD insertion
and can occur without warning.6-8 Animal studies have
demonstrated significant decreases in cardiac output after
repeated short intervals of VF,9 whereas longer periods of
VF resulted in profound heart failure.10
A considerable body of literature supports the capacity of
the sodium-hydrogen ion exchange inhibitors to attenuate
ischemia-reperfusion injury after regional or global isch-
emia by using energy metabolites or infarct size as indices
of ischemic damage. However, the ability of sodium-hydro-
gen exchange (NHE) inhibition to attenuate ventricular dys-
function after iatrogenic VF has not been reported. Inhibi-
tion of NHE during ischemia and reperfusion has been
shown to attenuate myocardial damage,11,12 reduce infarct
size,13,14 limit regional dysfunction,15 and attenuate arrhyth-
mias.16 NHE protection after global ischemia has been
studied as well in isolated heart preparations17-19 and in the
setting of orthotopic transplantation of hearts harvested after
normothermic ischemia.20-22 Cariporide, a selective NHE
inhibitor, has been shown to improve regional LV function
in patients with acute myocardial infarction undergoing
percutaneous transluminal coronary angioplasty23 and was
well tolerated by patients in the GUARDIAN trial,24 which
concluded that NHE inhibition could be beneficial in pa-
tients undergoing bypass surgery after infarction.
Consequently, we explored the possibility of pharma-
cologic protection from ventricular dysfunction in the
setting of iatrogenic VF. We investigated the use of one
of the newer members of the NHE family, benzamide-N-
(aminoiminomethl)-4-(4-[2-furanylcarbonyl]-1-piperazi-
nyl)-3-(methylsulfonyl)methanesulfonate (BIIB 513), a
selective NHE-1 inhibitor, untested in human beings.
Reagents were obtained from Boehringer Ingelheim
Pharma KG (Biberach, Germany). We used a pig model
because of the similarity of the porcine myocardium to
the human myocardium and its susceptibility to myocar-
dial ischemia.25
Materials and Methods
Overview
All animals received humane care in compliance with the “Prin-
ciples of Laboratory Animal Care” formulated by the National
Society for Medical Research and the “Guide for the Care and Use
of Laboratory Animals” prepared by the Institute of Laboratory
Animal Resources, National Research Council, and published by
the National Academy Press, revised 1996.
Twelve male domestic pigs weighing 32 to 45 kg were anes-
thetized with atropine sulfate (1-2 mg administered intramuscular-
ly), ketamine hydrochloride (20 mg/kg administered intramuscu-
larly), and acepromazine (0.5 mg/kg). They were intubated,
mechanically ventilated, and maintained on isoflurane
(1.5%-2.5%) mixed with 100% oxygen. A heating pad was used to
maintain body temperature. Arterial blood gases and serum elec-
trolytes were periodically checked to monitor oxygenation and
optimize ventilation. During the experiments, 0.9% saline solution
was administered through an 18-gauge angiocatheter in the fem-
oral vein at 10 mL  kg1  h1 for the first hour and then decreased
to 5 mL  kg1  h1 for the duration of the study, a protocol
developed in collaboration with laboratory veterinarians at Colum-
bia University.
After preliminary studies were performed in 2 animals to
determine an interval of VF that would produce reproducible
changes in ventricular function after 40 minutes of reperfusion,
animals were divided into 2 groups (control group, n  6; BIIB
513 group, n  6). Baseline hemodynamic indices were taken
before and after 75 seconds of VF and 40 minutes of reperfusion.
Hearts were subsequently arrested and excised, and postmortem
studies were performed.
Study Protocol
In vivo studies. While the electrocardiogram (ECG) and pe-
ripheral blood pressure were monitored with a fluid-filled catheter
(model 7758, 8-channel recording system, Hewlett-Packard), a
median sternotomy was performed. The hemiazygous vein (which
drains directly into the coronary sinus in pigs) was ligated, and a
longitudinal pericardiectomy was performed. A snare was placed
around the inferior vena cava. After systemic heparinization (100
U/kg), a calibrated 5F micromanometer pressure catheter (Millar
Instruments) and a 5F dual-field 12-electrode conductance catheter
with reversed configuration allowing apical placement (Millar
Instruments) were placed into the left ventricle through a 4-0
prolene purse-string suture in the LV apex. The position of the
conductance catheter was verified by means of 2-dimensional
epicardial echocardiography to ensure that the tip was through the
aortic valve and that contact of the electrodes with the endocar-
dium was avoided. Final position was adjusted by inspection of the
individual segment pressure-volume loops. By using an oscillo-
scope x/y plotter (Hewlett-Packard), counterclockwise rotation of
each of the 5 individual pressure-volume segment loops ensured
that each was within the LV cavity. Before data collection, a 6-mL
arterial blood sample was collected to measure blood resistivity
with the rho cuvette by using the Leycom Sigma- 5 conductance
module (Cardiodynamics DV). A pericardial well was created by
sewing a plastic sheet to the pericardium. The free edges of the
sheet were brought out and draped over the opened sternum. The
well was used to hold water-soluble echocardiography gel (Ultra-
phonic scanning gel, Pharmaceutical Innovations, Inc) around the
heart during echocardiographic measurements. The gel was re-
moved during conductance measurements. A 16-mm A-series tran-
sit time ultrasonic flow probe (Transonic Systems, Inc) was filled
with acoustic coupling gel and placed around the ascending aorta.
The probe was connected to a dual-channel flowmeter (HT207,
Transonic Systems, Inc). Finally, a pliable latex insulator was
placed under the heart to limit parallel conductance.26
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Echocardiograms were obtained (Vingmed CFM 800, GE Med-
ical) for LV cross-sectional short-axis measurements and for LV
volume determination by using a hand-held 5.0-MHZ ultrasound
transducer. The pericardial well was filled with scanning gel (Ul-
traphonic scanning gel, Pharmaceutical Innovations, Inc) to pro-
vide a standoff between the epicardium and the ultrasound trans-
ducer. Echocardiograms, LV pressure measurements, aortic flow
measurements, and ECGs were obtained in the steady state. Dis-
play of the ECG and calibrated LV pressure on the echocardiog-
raphy system facilitated synchronization of echocardiographic
frames with physiologic events.
After collection of baseline hemodynamic data (Table 1), pres-
sure-volume loops were generated during preload reduction
through caval occlusion. Before inferior vena caval occlusion, a
1-V deflection mark was recorded on the echocardiogram and on
the digital data acquired on the computer to allow the synchroni-
zation of the echocardiogram, ECG, LV end-diastolic pressure
value, and aortic flow value. After recovery of baseline blood
pressure, inflow occlusion was repeated during simultaneous LV
pressure and LV short-axis echocardiography recording with the
conductance catheter turned off. After collection of baseline he-
modynamic data, epicardial pacemaker leads were connected to
the anterior surfaces of the right and left ventricles. Animals were
then given 50 mL of 0.9% saline solution with or without 3 mg/kg
BIIB 513 according to protocols developed for this drug to provide
adequate drug levels 10 minutes after bolus injection.27 Ten min-
utes later, VF was induced for approximately 75 seconds with a
13-V 800-mA alternating current through a transformer (Archer
AC adapter, Radioshack; Figure 1). VF was terminated on cardio-
version with 50 J by using the internal paddles of a defibrillator
module (Hewlett-Packard). If cardioversion resulted in asystole,
animals were paced (Medtronic 5375) at 60 beats/min until hearts
regained an independent organized rhythm. This occurred in 4 of
the 12 animals evenly distributed between groups. One animal
given BIIB 513 had a fine VF that was unresponsive to cardiover-
sion or pacing. This animal could not be resuscitated and was
excluded from the study. After cardioversion, animals were al-
lowed to recover for 40 minutes, and hemodynamic data and
echocardiograms were again collected. At the beginning and con-
clusion of the experiment, a 10 mL-bolus of hypertonic saline (5%)
was infused directly into the pulmonary artery for measurement of
parallel conductance, as described below.
Postmortem studies. Hearts were arrested by means of infu-
sion of 3°C University of Wisconsin solution into the aortic root
after aortic crossclamping and transection of the inferior vena cava
and left inferior pulmonary vein. Hearts were rapidly excised and
placed in a 3°C ice slurry of University of Wisconsin solution.
Postmortem pressure-volume relationships were obtained as fol-
lows. An 18-gauge anigocatheter connected to one port of a 3-way
stopcock was placed through the previously performed LV apex
purse-string suture. The left ventricle was sealed by placing atrau-
matic clamps at the atrioventricular groove approximately 2 mm
above the mitral annulus. The clamp was positioned to minimize
annular compression or other distortions of LV geometry that
could induce artifacts.28 LV pressures were measured through a
second port of the stopcock by using the same 5F micromanom-
eter, as previously used after recalibration. The third port of the
stopcock was used for volume infusion. Before pressure measure-
ments, all air was eliminated from the system. Volume was infused
into the left ventricle in 5-mL increments, and micromanometer
pressure was recorded at a sampling rate of 200 points per second
by using an analog-to-digital conversion recording system
TABLE 1. Hemodynamic data before and after ischemia and reperfusion
Group
Baseline HR
(beats/min)
Baseline CO
(L/min)
Baseline
peak SBP
(mm Hg)
Duration
of VF (s)
Peak recovery
pressure
(mm Hg)
Time to
recovery of
baseline BP
(s)
HR p 40 min
(beats/min)
CO p 40 min
(L/min)
Peak SBP
p 40 min
(mm Hg)
Control 1 72 2.4 75 75 110 xx 84 2.3 80
Control 2 56 1 83 66 77 180 67 0.6 72
Control 3 56 2.3 90 80 100 185 56 1.6 55
Control 4 60 1.6 70 74 106 120 67 1.4 76
Control 5 83 2.4 90 76 120 150 76 1.5 85
Control 6 47 1.3 100 xx 147 xx 65 1.4 66
Average 62.33 1.83 84.67 74.20 110.00 158.75 69.17 1.47 72.33
SD 12.97 0.66 9.43 5.89 17.91 30.10 8.19 0.54 10.71
SEM 5.80 0.29 4.22 2.63 8.01 15.05 4.09 0.22 4.37
BIIB 1 61 2.1 67 89 140 120 64 3.4 58
BIIB 2 72 2.3 116 83 144 70 84 1.1 86
BIIB 3 75 1.8 87 63 169 130 89 1.5 121
BIIB 4 87 1.6 102 72 111 70 85 1.9 83
BIIB 5 82 1.3 91 73 107 90 95 2 100
BIIB 6 60 1.5 82 65 150 45 83 2.3 112
Average 75.40 1.82 92.60 76.00 134.20 87.50 83.40 1.98 89.60
SD 9.96 0.40 18.20 10.15 25.59 32.52 11.67 0.87 23.18
SEM 4.46 0.18 8.14 4.54 11.44 14.54 5.22 0.39 10.37
P value .10 .83 .47 .99 .076 .008 .03 .18 .18
Significant P values are shown in bold. HR, Heart rate; CO, cardiac output; SBP, systolic blood pressure; BP, blood pressure; p 40 min, after 40 minutes
of reperfusion; xx, data unavailable.
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(MacLab, ADInstruments, Inc). Volume was infused until an LV
pressure of 20 mm Hg was reached. The infused fluid was with-
drawn and measured to determine whether leakage had occurred.
In all animals, 95% or more of injected volume was recovered, and
therefore no data were excluded from the pressure-volume analysis
on this basis. This procedure was performed in duplicate for each
excised heart.
After pressure-volume data were collected, the aorta, pulmo-
nary artery, and atria were removed, and fat was trimmed. Excised
hearts were placed on a preweighed piece of aluminum foil and
weighed on an analytic balance (H16, Mettler Instruments Corp) to
obtain heart wet weight (WW). The hearts were then dried to a
constant weight in a 60°C oven for over 48 hours and reweighed
to obtain heart dry weight (DW). The percentage of myocardial
water content (MWC) was calculated as follows:
MWC (%) ([WW DW/WW]) 100%. (1)
Data Acquisition and Analysis
Amplified pressure, conductance, and aortic flow were sampled at
200 Hz and transferred through a 16-channel analog-to-digital
converter (MacLab, ADInstruments Inc) to a personal computer
(IMAC, Apple Computer). Data were analyzed with the use of
IGOR software (Wavemetrics, Inc). The total conductance signal
was generated and processed in a Sigma 5 DF unit. The principles
of conductance measurement of volume are described else-
where.29,30 Cumulative ejected volume determined by means of
conductance and recorded during caval occlusion was plotted
against the integrated aortic flow probe signal at each time point
during ventricular ejection; gain was derived as the gradient of the
linear regression. Correlation coefficients of the linear regression
greater than 0.95 with a slope of the regression line within 0.3 of
the line of identity (0.7-1.3) were accepted. Parallel conductance
was calculated by a modification of the hypertonic saline injection
method developed by Baan and associates.30
Calculation of systolic function. Calculation of indices of
systolic function during brief caval occlusion was performed with
more than 8 consecutive cycles free of ventricular ectopy. All data
were recorded with the ventilator off and measured at end expira-
tion. For each cycle during caval occlusion, LV stroke work was
calculated as the area of the pressure-volume loop. This was
plotted against the end-diastolic volume. Preload recruitable stroke
work (PRSW) was derived as the slope of the linear regression
between stroke work and end-diastolic volume.31 The greatest
slope of the pressure-volume relationship throughout the cardiac
cycle defined end systole, and the end-systolic pressure-volume
relationship (ESPVR) defined maximum systolic elastance.32
Calculation of diastolic function. The in vivo end-diastolic
ventricular compliance curves were calculated in two ways. In the
first method we used the conductance catheter to generate ventric-
ular volumes as described above to create LV end-diastolic pres-
sure-volume relationship (LV EDPVR) curves. In vivo LV ED-
PVR was obtained by superimposing the peak of the R wave of the
ECG on the LV pressure and volume tracings. To enable compar-
ison of animals of different sizes, LV raw volumes (V) were
normalized to an average dry heart weight (W) of 28.74 g by using
the following relationship:
Figure 1. Representative ECG, LV pressure tracing, and LV flow from a pig before and during induced VF.
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Vn  V(28.74/W). (2)
In the second method of calculating in vivo end-diastolic ventric-
ular compliance curves, we used echocardiography (as described
below) to generate LV pressure-normalized LV area relationships.
Postmortem LV passive pressure-volume relationships were
compared between groups by using methods previously de-
scribed.33,34 Briefly, a compliance curve was generated for each
animal by plotting cumulative volume-injected and measured LV
pressure. LV volumes were normalized to dry heart weight.
Echocardiographic analysis. Images were digitized during re-
al-time data acquisition by using the Vingmed CFM 800 echocar-
diography machine. End-diastolic short-axis cross-sectional im-
ages were planimetered by hand to obtain LV end-diastolic area.
Statistical Analysis
PRSW was compared within groups before and after ischemia and
reperfusion by using the Student t test. Comparisons between
groups for hemodynamic data both before and after ischemia and
reperfusion were made by using the Student t test. Pressure-
volume curves and equations were generated by using Proc Mixed
(SAS) methodology for repeated measurements. This method es-
timates the SEs by modeling the covariance structure of the re-
peated measures.35,36 These measures are inherently correlated
within the subject. Three of the more common covariance struc-
tures include compound symmetry for correlations that are constant
for any 2 points in time, autoregressive order one for correlations
that are smaller for time points further apart, and unstructured,
which has no mathematic pattern within the covariance matrix. It
was found that the autoregressive order one covariance structure
provided the best fit for the postmortem data. This was discerned
by means of comparing log likelihoods and the respective degrees
of freedom for a given 2 models at a time.
For the in vivo data, a logarithmic transformation of all pres-
sures was performed to exponentiate the data and provide the best
fit. A significant interaction term was the requirement for statisti-
cally significant difference among the groups. For the postmortem
data, a cubic polynomial function was fitted. P values were not
corrected (eg, Bonferonni) for the multiplicity of testing. All data
were analyzed by using SAS system software (SAS Institute Inc).
Results
Data for changes in PRSW are shown in Table 2 and Figure
2. PRSW for control animals was significantly reduced from
baseline after ischemia and reperfusion (27.7  2.5 vs
48.0  5.6 mm Hg [ SEM]; P  .001, paired Student t
test) but not in the BIIB 513 group (43.0  5.8 vs 45.5 
4.1 mm Hg, P  not significant). PRSW after ischemia and
reperfusion was significantly different between the 2 groups
(P  .04, unpaired Student t test). The x intercept of the
PRSW relationship did not change significantly after isch-
emia-reperfusion injury within or between groups. Data for
changes in EF are shown in Table 2. Average baseline EF
(36.8% 5.2% for the control group and 33.4% 4.3% for
the BIIB 513 group [ SEM]) was insignificantly reduced
by ischemia and reperfusion in both groups (31.2%  5.1%
for the control group and 32.7%  2.7% the for BIIB 513
group [ SEM], P  not significant). The average percent-
age change in EF showed trends toward decreased EF in
control animals that fell short of statistical significance
(15.54% for the control group and 2.63% for the BIIB
513 group; P  .178, Mann-Whitney test). ESPVRs are
reported in Table 2; preischemic values for the control and
TABLE 2. Ventricular function before and after ischemia and reperfusion
Group
PRSW before
(mm Hg)
PRSW
after
(mm Hg)
Vw
before
Vw
after
EF
before
(%)
EF
after
(%)
EF
delta
(%)
ESPVR
before
(mm Hg/mL)
ESPVR
after
(mm Hg/mL)
Control 1 35 21 39.41 47.88 xx xx xx 1.19 1.6
Control 2 61 30 xx xx 41.3 32.9 20.3 1.9 1.3
Control 3 41 25 8.43 16.35 52.6 49 6.8 4.6 1.2
Control 4 62 36 56.72 34.18 22.8 19.3 15.4 3.1 2.34
Control 5 35 22 26.7 26.34 31.5 28.7 8.9 1.4 1.26
Control 6 54 32 xx xx 35.6 26.3 26.3 xx xx
Average 48.00 27.67 32.82 31.19 36.76 31.24 15.54 2.44 1.54
SD 13.79 6.13 24.38 8.94 12.83 12.40 6.17 1.42 0.47
SEM 5.63 2.50 9.95 3.65 5.24 5.06 2.76 0.63 0.21
BIIB 1 27 24 xx xx 37.9 37.1 2.1 0.93 0.75
BIIB 2 53 32 62.22 41.86 40.9 32.7 20 1.83 1.46
BIIB 3 49 59 26.85 14.32 47 37 20.7 1.7 3.1
BIIB 4 42 39 3.64 4.74 18.1 19.4 7.2 1.68 2.27
BIIB 5 48 45 16.04 25.87 30.6 33.5 9.5 1.53 2.68
BIIB 6 54 59 51.1 27.68 25.8 36.6 41.9 3.43 6.38
Average 45.50 43.00 31.97 22.89 33.38 32.72 2.63 1.85 2.77
SD 10.01 14.24 24.31 14.09 10.59 6.79 23.19 0.84 1.96
SEM 4.09 5.81 10.87 6.30 4.32 2.77 9.47 0.34 0.80
P value .6991 .0393 NS NS NS NS .18 .41 .21
Vw, X intercept PRSW relationship; xx, data unavailable; NS, not statistically significant.
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BIIB 513 groups (2.44  0.6 vs 1.85  0.3 mm Hg/mL [
SEM]) are not significantly different than postischemic val-
ues (1.54  0.2 vs 2.77  0.8), although trends suggested
a decrease in ESPVR in the control group and an increase in
the BIIB 513 group.
Data for changes in baseline hemodynamics are pre-
sented in Table 1. The average time required to recover
baseline systolic blood pressure after VF was significantly
longer for the control group when compared with that of the
BIIB 513 group (158.75  15 vs 87.5  14.5 seconds [
SEM]; P  .008, Student t test). The average heart rate was
also significantly decreased in the control group (69.17  4
vs 83.4  5.2 beats/min [ SEM]; P  .03. Student t test).
Differences between the control and BIIB 513 groups in
postischemic early peak systolic pressure (110  8 vs
134  11 mm Hg [ SEM], P  .076), cardiac output
(1.47  0.46 vs 1.98  0.39 L/min [ SEM], P  .18) and
peak systolic blood pressure after 40 minutes (72.3 4.3 vs
89.6  10.4 mm Hg [ SEM], P  .18) all reflected trends
in decreased myocardial function in the control group but
fell short of significance.
Data for in vivo end-diastolic pressure-volume (calculat-
ed by means of conductance) relationships are represented
by Figure 3, A, and Table 3. Compliance reflected by the
slopes of the LV compliance curves was significantly di-
minished from baseline after ischemia-reperfusion injury in
the control group (0.021 0.044 pre vs 0.039 0.066 post;
P  .013) but remained unchanged after ischemia-reperfu-
sion injury in the experimental group (0.032  0.004 pre vs
0.034  0.0029 post; P  .594).
Data for in vivo end-diastolic pressure-area (calculated
by echocardiography) relationships are represented by Fig-
ure 3, B, and Table 4. These data demonstrate a similar
phenomenon, as observed when volume was measured by
means of conductance (diminished compliance in the con-
trol group after ischemia-reperfusion injury); however, dif-
ferences in the slopes of these compliance curves were not
statistically significant: control pre 0.266  0.05 vs control
post 0.332  0.080; P  .475; BIIB pre 0.295  0.050 vs
BIIB post 0.280  0.060; P  .850).
Data for postmortem end-diastolic pressure-volume rela-
tionships are presented in Figure 4 and Table 5. The differ-
Figure 2. Effect of BIIB 513 on PRSW after ischemia-reperfusion injury. The ordinate represents averaged PRSW
in millimeters of mercury, and the abscissa represents the time point in the experiment: PRE, baseline levels; POST,
40 minutes of reperfusion after VF. Filled squares and the dotted line represent values for the control group, and
open squares and the solid line represent values for the BIIB 513–pretreated group. SEs are represented by
brackets. Differences in PRSW for control animals after 40 minutes of reperfusion are significantly different from
those of control animals’ baseline levels and BIIB 513–pretreated animals after 40 minutes of reperfusion (P .005,
analysis of variance).
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ence in slopes of the compliance curves (control: y 
0.892  0.313 vol  0.002 vol2  0.0000315 vol3 vs
BIIB: y  0.621  0.195 vol  0.002 vol2  0.0000315
vol3) was statistically significant and indicated that the
control group had significantly lower volumes at any given
pressure demonstrative of a loss in ventricular compliance.
Data for myocardial water content and normalized LV
mass are presented in Table 6. Water content and normal-
ized LV mass in the control group (78.97%  0.94% SEM
and 137.24  6.17 g SEM, respectively) was increased
when compared with that in the BIIB 513 group (77.86% 
Figure 3. A, Effect of sodium-hydrogen ion exchange inhibition on in vivo EDPVRs (by means of conductance) after
ischemia-reperfusion injury. The ordinate represents end-diastolic LV pressure (in millimeters of mercury), and the
abscissa represents average end-diastolic volume (in milliliters) generated by means of conductance and
corrected for parallel conductance normalized to 28 g of dry heart weight (DHW). Filled symbols represent control
animals, and open symbols represent BIIB 513–pretreated animals. Squares represent baseline compliance, and
circles represent compliance after ischemia and reperfusion. Values of the average slopes and SEs of the
compliance curves are represented in Table 3. Ischemia and reperfusion in the control group led to a statistically
significant increase in slope (P  .0128), demonstrating a decrease in compliance (smaller volumes at any given
pressure), whereas for the BIIB 513 group, ischemia-reperfusion injury led to a statistically insignificant shift to the
right (greater volumes at any given pressure). B, Effect of sodium-hydrogen ion exchange inhibition on in vivo
end-diastolic pressure-area (by means of echocardiography) relationship after ischemia-reperfusion injury. The
ordinate represents end-diastolic LV pressure (in millimeters of mercury), and the abscissa represents averaged
end-diastolic area generated by means of echocardiography normalized to 28 g of dry heart weight (DHW). Filled
symbols represent control animals, and open symbols represent BIIB 513–pretreated animals. Squares represent
baseline compliance, and circles represent average compliance after ischemia and reperfusion. Values of the
average slopes and SEs of the compliance curves are represented by Table 4. Ischemia-reperfusion injury in the
control group led to a statistically insignificant shift to the left (lesser volumes at any given pressure), whereas in
the BIIB 513 group it led to a statistically insignificant shift to the right (greater volumes at any given pressure).
TABLE 3. Slopes of in vivo LV compliance curves (LV
volume by conductance)
Group Slope  SE
Control before 0.021 0.0044*
Control after 0.039 0.0058
BIIB before 0.032 0.0036†
BIIB after 0.034 0.0029
*P  .0128 versus control after.
†P  .5939 versus BIIB after.
TABLE 4. Slopes of in vivo LV compliance curves (LV area
by echocardiography)
Group Slope  SE
Control before 0.266 0.05*
Control after 0.332 0.08
BIIB before 0.295 0.05†
BIIB after 0.280 0.06
*P  .4753 versus control after.
†P  .8494 versus BIIB after.
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0.46% and 128.41  1.96 g, SEM) but did not reach
statistical significance.
Discussion
The present study indicates that NHE inhibition preserves
LV myocardial contractility and attenuates loss in LV com-
pliance after 75 seconds of VF. This is reflected by signif-
icant differences in both systolic (PRSW) and diastolic
indices (in vivo and postmortem compliance curves) before
and after ischemia-reperfusion injury for control animals,
whereas experimental animals’ indices were unchanged.
The protective effect of NHE inhibition is also reflected by
greater time to recovery of baseline systolic blood pressure
in control animals after VF and trends toward diminished
postischemic cardiac output and peak systolic blood pres-
sure in control animals. Additionally, the protective effect is
supported by statistically insignificant decreases in EF and
ESPVR and increases in myocardial edema and normalized
LV mass in control animals when compared with animals
receiving BIIB 513.
This study was designed to assess the effects of ischemia
and reperfusion. Although electrical defibrillation can cause
direct myocardial cell injury, leading to postischemic myo-
cardial dysfunction, significant injury only occurs at energy
levels far exceeding those used to reverse VF in the current
study.37 Negligible or no injury has been reported after
single countershocks at energy levels comparable with those
used in our study.38,39
Clinically, NHE inhibition has been tested unsuccess-
fully for the prevention of myocardial infarction and mor-
tality during percutaneous transluminal coronary angio-
plasty or surgical revascularization.24 The present results
suggest NHE inhibition could prove valuable for prevention
of ventricular dysfunction during ICD insertion. The dura-
Figure 4. Effect of BIIB 513 on postmortem passive pressure-volume relationship after ischemia-reperfusion injury.
The ordinate represents averaged end-diastolic LV pressure, and the abscissa represents averaged LV volume
normalized to 28 g of dry heart weight (DHW). Filled symbols represent values for control animals, and open
symbols represent values for BIIB 513–pretreated animals. Curves are fit as a cubic polynomial function. Control
animals had an averaged postmortem compliance curve, with a statistically significantly steeper slope (P  .0001)
representing a decrease in compliance.
TABLE 5. Formulas of postmortem LV passive pressure-
volume curves
Group Formula
Control y  0.892  0.313vol  0.002vol2  0.0000315vol3*
BIIB y  0.621  0.195vol  0.002vol2  0.0000315vol3
*P  .0001 versus BIIB.
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tion of VF used in the present study is longer than that
usually used during ICD insertion but not outside the range
previously reported.8 Furthermore, normal baseline ventric-
ular function in the animals used here contrasts markedly
with the diminished function commonly observed in ICD
recipients.
Mortality and morbidity during ICD insertion can be due
either to LV power failure or acute myocardial ischemia
related to underlying coronary artery disease. Although not
widely reported, DFT testing might be deferred in the high-
est-risk patients rather than risking death or serious injury as
a result of testing. The present results suggest that NHE
inhibition could provide increased safety for DFT testing in
ICD recipients both by ameliorating power failure and lim-
iting ischemic injury. In contrast to cariporide, BIIB 513 is
a relatively novel agent that has not yet been used in clinical
trials nor has its effect on DFT testing been investigated.
This would need to be done experimentally before clinical
use for this indication. We speculate that the observed
protective effect of BIIB 513 is likely the result of limita-
tions of increases of intracellular calcium concentration
during ischemia, resulting in reduced reperfusion-induced
calcium overload. Because animals were subjected to re-
peated episodes of limited ischemia during preload reduc-
tion from caval occlusions, it is worth considering the
possibility of a role for ischemic preconditioning and/or
myocardial stunning in our experiment, although significant
differences between animals protected by NHE inhibition
and controls suggests that the drug itself played an impor-
tant role in observed differences in ventricular function after
ischemia-reperfusion injury.
Our porcine model appears more vulnerable to myocar-
dial ischemia than other experimental models. Variable
degrees of potentially reversible systolic dysfunction have
been reported after resuscitation from cardiac arrest in an-
imal40-42 and human43 models; however, these ischemic
intervals were considerably longer than 75 seconds. For
example Kern42 demonstrated severe ventricular dysfunc-
tion after 10 to 15 minutes of VF in intact swine hearts.
Animals were resuscitated with dopamine and epinephrine.
By 24 hours, invasive and noninvasive measures of systolic
and diastolic LV function had begun to improve. At 48
hours, all measures of LV function had returned to baseline
levels.
The present results confirm that load-dependent indices
of systolic ventricular function, such as EF and ESPVR, are
less sensitive indices than PRSW. Trends in EF and ESPVR
in our study, however, reflect a pattern consistent with the
PRSW data and together provide convincing evidence that
there is a sustained decrease in systolic ventricular function
after just 75 seconds of VF in the healthy pig heart.
Although ischemia and reperfusion generally results in
impaired diastolic function in the intact heart,42 some con-
tradictory evidence has been described in isolated hearts and
trabeculae.41,44 A recent study in the isolated rat heart dem-
onstrated that NHE inhibition ameliorated ischemic contrac-
ture, prevented postresuscitation diastolic dysfunction, and
favored earlier return of contractile function after 25 min-
utes of iatrogenic VF.45 Previous studies in pigs have sug-
gested that diastolic dysfunction is worse immediately after
resuscitation and improves throughout the reperfusion peri-
od.42 Ischemic contracture has been reported as a cause of
TABLE 6. Animal and heart weights and myocardial water content
Group BW (kg) Wet HW (g)
Normalized
WHW (g) Dry HW (g) MWC (%)
Control 1 45 xx xx xx xx
Control 2 36 153 154.51 28.46 81.40
Control 3 35 125 149.31 24.06 80.75
Control 4 43 145.4 131.08 31.88 78.07
Control 5 40 127 121.10 30.14 76.27
Control 6 35 104 132.84 22.5 78.37
Average 39.00 130.88 137.24 27.41 78.97
SD 4.34 19.19 13.79 4.00 2.09
SEM 1.77 8.58 6.17 1.79 0.94
BIIB 1 45 151 129.47 33.52 77.80
BIIB 2 30 xx xx 30.95 xx
BIIB 3 30 121.29 135.78 25.673 78.83
BIIB 4 35 112 125.05 25.74 77.02
BIIB 5 35 103 123.34 24 76.70
BIIB 6 40 149 129.00 31.4 78.93
Average 35.00 121.82 128.41 27.98 77.86
SD 5.85 21.76 4.81 3.88 1.02
SEM 2.39 9.73 1.96 1.59 0.46
P value .32 .73 .19 .64 .48
BW, Body weight; HW, heart weight; WHW, wet heart weight; MWC, myocardial water content; xx, data unavailable.
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reduced diastolic compliance, but the duration of ischemia
in our study is too short to support this mechanism.
A comparison of the EDPVR from the postischemic in
vivo studies and postmortem studies reveals curves of dif-
ferent shapes; in vivo data were fit to exponential curves,
whereas postmortem data fit cubic functions better. This
might be the consequence of differences in volume mea-
surements (the conductance catheter was used in vivo, and
direct volume infusion was used postmortem), or it might be
the result of ischemic contracture resulting from the arrest
or the ischemic period during calculation of the EDPVR.
However, all postmortem studies were done within 15 min-
utes of cardiac arrest, whereas ischemic contracture does not
occur in the pig heart, even after considerably longer peri-
ods of time.48 A similar relationship in EDPVRs between
the control animals and animals pretreated with BIIB 513
was evident in the postmortem studies compared with in the
in vivo postischemic studies, suggesting that postmortem
EDPVR accurately reflects in vivo changes in compliance.
Baseline effects of BIIB 513 administration on hemody-
namics included a higher peak systolic pressure and heart
rate compared with that in control animals, but these were
not statistically significant (Table 1). The heart rate of
experimental animals was also higher after 40 minutes of
reperfusion, with comparable derived averaged stroke vol-
umes (21 mL/beat for the control group vs 24.5 mL/beat for
the BIIB 513 group). This difference might reflect an atten-
uated response to catecholamine stimulation in stunned
myocardium. It might also be related to pre-existing differ-
ences between the 2 populations; the control animals had an
average baseline heart rate of 62  6 beats/min compared
with 75 4.5 beats/min in the BIIB 513 group, a difference
that approached significance (P  .10, Student t test).
The only animal in our study that could not be resusci-
tated after induction of VF had been given BIIB 513. As
described above, the animal had a fine VF that was not
terminated on multiple attempts at cardioversion and from
which the animal could not be paced. This deserves further
consideration, along with the effect of NHE inhibition on
DFT testing.
Limitations of this study include the lack of documented
serum drug levels (despite following protocols previously
demonstrated to provide adequate drug levels) and the use
of anesthesia not commonly used during ICD insertion.
Additionally, this study was performed in healthy animals,
while often in the clinical arena ICDs are inserted in patients
with severe cardiomyopathies. Consequently, future studies
should focus on enhancing clinical relevance of these data
by using cariporide (HOE642), which has already been
demonstrated to be safe in human subjects, and by better
simulating the anesthetic conditions under which ICD in-
sertion is performed.
We thank Dr Randolph W. Seidler, Boehringer Ingelheim
Pharma KG; Dr Lee Huang; Mrs Ivelisse Castro; Ms May Deut-
sch; Ms Caroline Pitney; and Dr Mauricio Dawgs Garrido.
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